/
Description of Business In this Annual Report, except as the context suggests otherwise, the words Regional Health or Regional refer to Regional Health Properties, Inc., a Georgia corporation, and the words Company, we, our, and us refer to Regional Health and its subsidiaries. Regional Health Properties is a healthcare company that owns, operates and invests in healthcare real estate and opera…
$1.02
$0.05 (-5.12%)
EOD Jul 17, 2026
Net margin is thin at 5.73%. This may reflect rising credit costs, rate compression, or operational inefficiency.
Revenue grew 189.9% YoY.
Financial stocks carry unique risks (credit cycles, regulatory changes, interest rate sensitivity) that aren't captured by standard quality metrics.
0.6x earnings. Below the sector average, the market may be pricing in credit losses or regulatory headwinds, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$67M
▲ +189.9% YoY
Net Income (TTM)
$3M
▲ +194.6% YoY
Net Margin
4.69%
P/E
0.6x
Balance Sheet
Total Assets
$67M
Equity
-$962K
Total Debt
$42M
Cash & Equiv.
$1M
5Y CAGR: +24.8%
Continue Research
At a P/E of 0.6, Regional Health Properties (RHEP)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Regional Health Properties scores 30/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Regional Health Properties scores 30 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 1.9% operating margin and a 2.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh RHEP's valuation and scores 30/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.